Fintel reports that on August 10, 2023, Craig-Hallum kept protection of Biolife Solutions (NASDAQ: BLFS) with a Buy suggestion. Expert Price Forecast Suggests 147.55% Upside As of August 2, 2023, the typical 1 year rate target for Biolife Solutions is 30.75. The projections vary from a low of 27.27 to a high of $35.70. The typical rate target represents a boost of 147.55% from its newest reported closing rate of 12.42. See our leaderboard of business with the biggest cost target upside. The predicted yearly profits for Biolife Solutions is 200MM, a boost of 23.29%. The predicted yearly non-GAAP EPS is -0.44. What is the Fund Sentiment? There are 396 funds or organizations reporting positions in Biolife Solutions. This is a decline of 1 owner(s) or 0.25% in the last quarter. Typical portfolio weight of all funds devoted to BLFS is 0.19%, a boost of 3.23%. Overall shares owned by organizations increased in the last 3 months by 0.56% to 45,177 K shares. The put/call ratio of BLFS is 0.22, showing a bullish outlook. What are Other Shareholders Doing? Casdin Capital holds 7,572 K shares representing 17.41% ownership of the business. In it’s previous filing, the company reported owning 7,566 K shares, representing a boost of 0.07%. The company increased its portfolio allowance in BLFS by 27.11% over the last quarter. IJR – iShares Core S&P Small-Cap ETF holds 2,488 K shares representing 5.72% ownership of the business. In it’s previous filing, the company reported owning 2,535 K shares, representing a reduction of 1.91%. The company increased its portfolio allowance in BLFS by 13.94% over the last quarter. Fred Alger Management holds 1,925 K shares representing 4.43% ownership of the business. In it’s previous filing, the company reported owning 1,978 K shares, representing a reduction of 2.74%. The company increased its portfolio allowance in BLFS by 14.77% over the last quarter. AOFAX – Alger Small Cap Focus Fund holds 1,675 K shares representing 3.85% ownership of the business. In it’s previous filing, the company reported owning 1,745 K shares, representing a decline of 4.18%. The company reduced its portfolio allotment in BLFS by 16.35% over the last quarter. Geneva Capital Management holds 1,559 K shares representing 3.58% ownership of the business. In it’s previous filing, the company reported owning 1,520 K shares, representing a boost of 2.48%. The company increased its portfolio allowance in BLFS by 177,518.41% over the last quarter. Biolife Solutions Background Information (This description is offered by the business.) BioLife Solutions is a prominent provider of cell and gene treatment bioproduction services and products. Its product or services portfolio includes its exclusive CryoStor ® freeze media, HypoThermosol ® shipping and storage media, ThawSTAR ® household of automated, water-free thawing items, evo ® cold chain management system, and Custom Biogenic Systems high capability storage freezers and SciSafe biologic storage services. Extra reading: BioLife Solutions Reports Second Quarter 2023 Financial Results, Updates Full Year 2023 Guidance and Provides Pro Forma First Half 2023 Financial Profile Excluding Freezer Business Committed to Divesting Stirling Ultracold and Custom Biogenic Systems BioLife Solutions Reports First Quarter 2023 Financial Results Revenue of $37.7 million increased 4% over Q1 2022, ex-COVID development of 16% and biopreservation media income development of 28% Q1 2023 Adjusted gross margin enhancement; 37% compared to 32% i List of the Company’s Subsidiaries Extension and Amendment of Lease outdated December 19, 2022 for center area 3505 and 3507 Edison Way, Menlo Park, CA 94025 (submitted herewith) Employment Agreement dated November 9, 2021 in between the Company and Geraint Phillips (submitted herewith) This story initially appeared on Fintel. The views and viewpoints revealed herein are the views and viewpoints of the author and do not always show those of Nasdaq, Inc.
Craig-Hallum Maintains Biolife Solutions (BLFS) Buy Recommendation
